This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (119)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Schizophrenia  • Alert me on articles by topic

Association of Promoter Variants in the 7 Nicotinic Acetylcholine Receptor Subunit Gene With an Inhibitory Deficit Found in Schizophrenia

Sherry Leonard, PhD; Judith Gault, PhD; Jan Hopkins, BS; Judith Logel, MS; Ruby Vianzon, BS; Margaret Short, BS; Carla Drebing, BS; Ralph Berger, BS; Diana Venn; Pinkhas Sirota, MD; Gary Zerbe, PhD; Ann Olincy, MD; Randal G Ross, MD; Lawrence E. Adler, MD; Robert Freedman, MD

Arch Gen Psychiatry. 2002;59:1085-1096.

Background  The 7 neuronal nicotinic acetylcholine receptor subunit gene (CHRNA7) has been implicated as a candidate gene for schizophrenia, and for an auditory sensory processing deficit found in the disease, by both genetic linkage at 15q14 and biochemical data. The expression of CHRNA7 is reduced in several brain regions in schizophrenic subjects compared with control subjects. This study presents DNA sequence analysis of the core promoter region for CHRNA7 in schizophrenic and control subjects.

Methods  Single-strand conformation polymorphism analysis and DNA sequencing were used for mutation screening of the core promoter in the CHRNA7 gene. The sample included subjects from 166 schizophrenic families and 165 controls. Controls had no evidence of current or past psychosis and had auditory evoked potentials recorded.

Results  Multiple polymorphic patterns were identified in the CHRNA7 core promoter in both schizophrenic and control subjects. Functional analysis of polymorphisms indicated that transcription was reduced. The prevalence of functional promoter variants was statistically greater in schizophrenic subjects than in the controls. Presence of an 7 promoter polymorphism in controls was associated with failure to inhibit the P50 auditory evoked potential response.

Conclusions  Although linkage disequilibrium with other genetic alterations cannot be excluded, the CHRNA7 core promoter variants, found in this study, may contribute to a common pathophysiologic feature of schizophrenia.

From the Departments of Psychiatry (Drs Leonard, Gault, Olincy, Ross, Adler, and Freedman; Mss Logel, Vianzon, Drebing, and Venn; and Mr Berger), Pharmacology (Drs Leonard and Freedman), and Preventive Medicine and Biometrics (Dr Zerbe), University of Colorado Health Sciences Center, and the Denver Veterans Affairs Medical Center (Drs Leonard, Olincy, Ross, Adler, and Freedman and Mss Hopkins and Short), Denver; and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Dr Sirota).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased {alpha}-Defensins as a Blood Marker for Schizophrenia Susceptibility
Craddock et al.
Mol. Cell. Proteomics 2008;7:1204-1213.
ABSTRACT | FULL TEXT  

Use of the ADOS and ADI-R in children with psychosis: importance of clinical judgment.
Reaven et al.
Clinical Child Psychology and Psychiatry 2008;13:81-94.
ABSTRACT  

[3H]A-585539 [(1S,4S)-2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a Novel High-Affinity {alpha}7 Neuronal Nicotinic Receptor Agonist: Radioligand Binding Characterization to Rat and Human Brain
Anderson et al.
J. Pharmacol. Exp. Ther. 2008;324:179-187.
ABSTRACT | FULL TEXT  

Physiology of Schizophrenia, Bipolar Disorder, and Schizoaffective Disorder
Martin et al.
Am. J. Psychiatry 2007;164:1900-1906.
ABSTRACT | FULL TEXT  

{alpha}7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1
Mathew et al.
Hum Mol Genet 2007;16:2921-2932.
ABSTRACT | FULL TEXT  

Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia: The Consortium on the Genetics of Schizophrenia
Greenwood et al.
Arch Gen Psychiatry 2007;64:1242-1250.
ABSTRACT | FULL TEXT  

Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use
ZAMMIT et al.
Br. J. Psychiatry 2007;191:402-407.
ABSTRACT | FULL TEXT  

An Allosteric Modulator of the {alpha}7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in Vivo
Timmermann et al.
J. Pharmacol. Exp. Ther. 2007;323:294-307.
ABSTRACT | FULL TEXT  

Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at {alpha}7* Nicotinic Receptors
Lopes et al.
J. Pharmacol. Exp. Ther. 2007;322:48-58.
ABSTRACT | FULL TEXT  

{alpha}7 Nicotinic Receptor Gene Promoter Polymorphisms in Inbred Mice Affect Expression in a Cell Type-specific Fashion
Mexal et al.
J. Biol. Chem. 2007;282:13220-13227.
ABSTRACT | FULL TEXT  

Novel G423S Mutation of Human {alpha}7 Nicotinic Receptor Promotes Agonist-Induced Desensitization by a Protein Kinase C-Dependent Mechanism
Tsuneki et al.
Mol. Pharmacol. 2007;71:777-786.
ABSTRACT | FULL TEXT  

Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky et al.
Schizophr Bull 2007;33:69-94.
ABSTRACT | FULL TEXT  

Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Potter et al.
Schizophr Bull 2006;32:692-700.
ABSTRACT | FULL TEXT  

Proof-of-Concept Trial of an {alpha}7 Nicotinic Agonist in Schizophrenia.
Olincy et al.
Arch Gen Psychiatry 2006;63:630-638.
ABSTRACT | FULL TEXT  

Dysregulation of thalamic sensory 'transmission' in schizophrenia: neurochemical vulnerability to hallucinations
Behrendt
J Psychopharmacol 2006;20:356-372.
ABSTRACT  

Cognitive Deficits in Unaffected First-Degree Relatives of Schizophrenia Patients: A Meta-analytic Review of Putative Endophenotypes
Snitz et al.
Schizophr Bull 2006;32:179-194.
ABSTRACT | FULL TEXT  

Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia: Involvement of Nicotinic Receptor Mechanisms
Sacco et al.
Arch Gen Psychiatry 2005;62:649-659.
ABSTRACT | FULL TEXT  

A Concordance Study of Three Electrophysiological Measures in Schizophrenia
Louchart-de la Chapelle et al.
Am. J. Psychiatry 2005;162:466-474.
ABSTRACT | FULL TEXT  

The Selective {alpha}7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats
Hajos et al.
J. Pharmacol. Exp. Ther. 2005;312:1213-1222.
ABSTRACT | FULL TEXT  

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders
Sacco et al.
J Psychopharmacol 2004;18:457-474.
ABSTRACT  

Varied Effects of Atypical Neuroleptics on P50 Auditory Gating in Schizophrenia Patients
Adler et al.
Am. J. Psychiatry 2004;161:1822-1828.
ABSTRACT | FULL TEXT  

Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study
Weiser et al.
Am. J. Psychiatry 2004;161:1219-1223.
ABSTRACT | FULL TEXT  

Autonomic Nervous System Pharmacogenomics: A Progress Report
Kirstein and Insel
Pharmacol. Rev. 2004;56:31-52.
ABSTRACT | FULL TEXT  

Schizophrenia
Freedman
NEJM 2003;349:1738-1749.
FULL TEXT  

The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman and Gould
Am. J. Psychiatry 2003;160:636-645.
ABSTRACT | FULL TEXT  

Connecting a Schizophrenia Gene with Deficient Sensory Gating
JWatch Psychiatry 2003;2003:7-7.
FULL TEXT